---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-266184"
form_type: "8-K"
ticker: "JAZZ"
cik: "0001232524"
company_name: "Jazz Pharmaceuticals plc"
filed_at: "2024-11-26T23:59:59+00:00"
generated_at: "2026-05-29T17:33:26.983670+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Jazz Pharmaceuticals expands revolver to $885M, extends maturity to 2029

## Summary
- Revolving credit facility increased from $500M to $885M; maturity extended from May 2026 to Nov 2029.
- Initial applicable margin reduced by 125 bps: Term SOFR +2.00% and prime +1.00%.
- Facility was undrawn as of Nov 26, 2024; financial covenants apply only when drawn.
- Springing maturity provisions tied to 2026 exchangeable notes and 2028 term loan thresholds.
- Amendment adds new lenders and commits to customary conditions for effectiveness.

## SEC filing metadata
- accession: 0001193125-24-266184
- form_type: 8-K
- ticker: JAZZ
- cik: 0001232524
- company_name: Jazz Pharmaceuticals plc
- filed_at: 2024-11-26T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 2.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1232524/000119312524266184/0001193125-24-266184-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1232524/000119312524266184/d833314d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-266184
- JSON: https://secwatch.observer/filing/0001193125-24-266184.json
- Plain text: https://secwatch.observer/filing/0001193125-24-266184.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.